Back to News
Market Impact: 0.25
KORTUC Achieves Target Enrollment in Registrational Breast Cancer Trial as Three Global Clinical Programs Advance
Source: GlobeNewswire
Healthcare & BiotechCorporate Guidance & Outlook
KORTUC reached 184 enrolled patients in its lead clinical program, advancing the study toward a planned readout. The company is also progressing a cervical-cancer study with UC San Diego and received authorization for its K-BOOST rectal program, expanding its clinical development pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Why Dave & Buster's Stock Tumbled Today
- Flotek Industries director Matthew Wilks adds $34.3m to holdings
- Trump calls AI fears a 'hoax', Treasury yields surge, Moynihan's warning and more in Morning Squawk
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors